TMCnet News
Global Gastric Ulcers Therapeutics Report 2016: Pipeline Review of 5 Companies & 7 Molecules - Research and MarketsResearch and Markets has announced the addition of the "Gastric Ulcers - Pipeline Review, H2 2016" report to their offering. 'Gastric Ulcers - Pipeline Review, H2 2016' Gastric Ulcers pipeline therapeutics constitutes close to 7 molecules, out of which approximately 7 molecules are developed by Companies. Furthermore, the publisher says, Gastric ulcer is a painful sore or ulcer in the lining of the stomach. The most common cause of gastric ulcer is Helicobacter pylori bacterial infection. Symptoms include pain, bloating, retching, nausea or vomiting and unexplained weight loss. Predisposing factors include smoking and alcoholism. Treatment includes antibiotics and antacids. 'Gastric Ulcers - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Gastric Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route f administration (RoA) and molecule type, that are being developed by Companies / Universities. It also reviews of key players involved in therapeutic development for Gastric Ulcers and features dormant and discontinued projects. Currently, The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4 and 1 respectively. Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/6mqkpn/gastric_ulcers
View source version on businesswire.com: http://www.businesswire.com/news/home/20161020006437/en/ |
